Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients
Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients
(2023)
Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients
Anno:
2023
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Lingua:
Inglese
Referee:
No
Nome rivista:
Journal of the European Academy of Dermatology and Venereology
ISSN Rivista:
0926-9959
Intervallo pagine:
100-102
Parole chiave:
psoriasis risankizumab safety
Breve descrizione dei contenuti:
safety of risankizumab in patients with psoriasis and hepatitis B and C
Id prodotto:
133872
Handle IRIS:
11562/1094248
ultima modifica:
31 ottobre 2024
Citazione bibliografica:
Ciolfi, Christian; Balestri, Riccardo; Bardazzi, Federico; Burlando, Martina; Chersi, Karin; Costanzo, Antonio; Dapavo, Paolo; Gisondi, Paolo; Malagoli, Piergiorgio; Pizzolato, Miriam; Rech, Giulia; Paolo Russo, Francesco; Battistella, Sara; Piaserico, Stefano,
Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients«Journal of the European Academy of Dermatology and Venereology»
, 2023
, pp. 100-102